Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.41 |
| ▸ | CDK1 | P06493 | 4/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.41 |
| ▸ | CDK4 | P11802 | 3/20 | 0.41 |
| ▸ | CCND1 | P24385 | 3/20 | 0.41 |
| ▸ | CCND2 | P30279 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5725547 | 1.00 | FLT3 (0.46) | FLT3CDK2CDK7CDK9MAPK14 | |
| SCHEMBL6249487 | 0.88 | OGA (0.43) | FLT3NPC1RAB9AOGAADORA3 | |
| SCHEMBL6249483 | 0.88 | OGA (0.43) | FLT3NPC1RAB9AOGAADORA3 | |
| SCHEMBL5725120 | 0.85 | CDK2 (0.55) | CDK2CDK7CDK9CCNB2CCNE2 | |
| SCHEMBL5725111 | 0.85 | CDK2 (0.55) | CDK2CDK7CDK9CCNB2CCNE2 | |
| SCHEMBL5725140 | 0.85 | CDK2 (0.55) | CDK2CDK7CDK9CCNB2CCNE2 | |
| SCHEMBL5725801 | 0.84 | CDK2 (0.47) | FLT3CDK2CDK7CDK9MAPK14 | |
| SCHEMBL5725830 | 0.84 | CDK2 (0.47) | FLT3CDK2CDK7CDK9MAPK14 | |
| SCHEMBL5726934 | 0.84 | CDK2 (0.44) | CDK2CDK7CDK9MAPK14MAPK13 | |
| SCHEMBL5726919 | 0.84 | CDK2 (0.44) | CDK2CDK7CDK9MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087951-B9 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | claimed |
| EP-1087951-B1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | EP | claimed |
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | RAWLINS DAVID B (US) | 2002-11-07 | — | — | US | claimed |
| EP-1087951-A4 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-08-14 | — | — | EP | claimed |
| EP-1087951-A1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065884-A1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | CCNK, CDK2, CCNL2 | FLT3 990/4885CDK2 2/4885CDK7 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.